{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:49:19Z","timestamp":1791319759120,"version":"4.3.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"DOI":"10.1186\/s12893-024-02526-9","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T01:02:07Z","timestamp":1728003727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of intraperitoneal chemotherapy for pancreatic cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Dorsa","family":"Safari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fakhrolmobasheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Soleymanjahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"1","key":"2526_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"Ca Cancer J Clin"},{"issue":"3","key":"2526_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ags3.12655","volume":"7","author":"S Yasuda","year":"2023","unstructured":"Yasuda S, Nagai M, Terai T, Kohara Y, Sho M. Essential updates 2021\/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2023;7(3):358\u201366.","journal-title":"Ann Gastroenterol Surg"},{"issue":"1","key":"2526_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1245\/s10434-022-12328-z","volume":"30","author":"TE Grotz","year":"2023","unstructured":"Grotz TE, Yonkus JA, Thiels CA, Warner SG, McWilliams RR, Mahipal A, Bekaii-Saab TS, Cleary SP, Kendrick ML, Truty MJ. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with low-volume peritoneal metastasis: results from a prospective pilot study. Ann Surg Oncol. 2023;30(1):395\u2013403.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2526_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.5858\/133.3.413","volume":"133","author":"S Yachida","year":"2009","unstructured":"Yachida S, Iacobuzio-Donahue CA. The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med. 2009;133(3):413\u201322.","journal-title":"Arch Pathol Lab Med"},{"key":"2526_CR5","doi-asserted-by":"crossref","unstructured":"Gudmundsdottir H, Yonkus JA, Thiels CA, Warner SG, Cleary SP, Kendrick ML, Truty MJ, Grotz TE. Oncologic outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for highly selected patients with metastatic pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2023.","DOI":"10.1245\/s10434-023-14138-3"},{"issue":"1","key":"2526_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/XCS.0000000000000704","volume":"237","author":"H Gudmundsdottir","year":"2023","unstructured":"Gudmundsdottir H, Yonkus JA, Alva-Ruiz R, Kendrick ML, Smoot RL, Warner SG, Starlinger P, Thiels CA, Nagorney DM, Cleary SP. Yield of staging Laparoscopy for Pancreatic Cancer in the modern era: analysis of more than 1,000 consecutive patients. J Am Coll Surg. 2023;237(1):49.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"2526_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1634\/theoncologist.2014-0394","volume":"20","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20(2):143\u201350.","journal-title":"Oncologist"},{"issue":"5","key":"2526_CR8","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1245\/s10434-022-13010-0","volume":"30","author":"M Graversen","year":"2023","unstructured":"Graversen M, Detlefsen S, Ainsworth AP, Fristrup CW, Knudsen AO, Pfeiffer P, Tarpgaard LS, Mortensen MB. Treatment of peritoneal metastasis with pressurized Intraperitoneal Aerosol Chemotherapy: results from the prospective PIPAC-OPC2 study. Ann Surg Oncol. 2023;30(5):2634\u201344.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2526_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-016-0767-y","volume":"14","author":"S Satoi","year":"2015","unstructured":"Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, Opendro SS, Inoue K, Michiura T, Ryota H. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol. 2015;14(1):1\u20138.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"2526_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jhbp.1085","volume":"29","author":"S Satoi","year":"2022","unstructured":"Satoi S, Takahara N, Fujii T, Isayama H, Yamada S, Tsuji Y, Miyato H, Yamaguchi H, Yamamoto T, Hashimoto D. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. J Hepato-Biliary\u2010Pancreatic Sci. 2022;29(6):600\u20138.","journal-title":"J Hepato-Biliary\u2010Pancreatic Sci"},{"issue":"2","key":"2526_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","volume":"265","author":"S Satoi","year":"2017","unstructured":"Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, Yamada S, Yamamoto T, Mizuma M, Honda G. Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg. 2017;265(2):397\u2013401.","journal-title":"Ann Surg"},{"key":"2526_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10637-020-00982-7","volume":"39","author":"N Takahara","year":"2021","unstructured":"Takahara N, Nakai Y, Ishigami H, Saito K, Sato T, Hakuta R, Ishigaki K, Saito T, Hamada T, Mizuno S. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Investig New Drugs. 2021;39:175\u201381.","journal-title":"Investig New Drugs"},{"issue":"7","key":"2526_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","volume":"89","author":"RL Dedrick","year":"1997","unstructured":"Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89(7):480\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"2526_CR14","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","volume":"26","author":"W Sola\u00df","year":"2012","unstructured":"Sola\u00df W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26:1849\u201355.","journal-title":"Surg Endosc"},{"issue":"1","key":"2526_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ags3.12295","volume":"4","author":"S Satoi","year":"2020","unstructured":"Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Annals Gastroenterological Surg. 2020;4(1):6\u201313.","journal-title":"Annals Gastroenterological Surg"},{"key":"2526_CR16","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Satoi S, Yamaki S, Hashimoto D, Ishida M, Ikeura T, Hirooka S, Matsui Y, Boku S, Nakayama S et al. Intraperitoneal Paclitaxel Treatment for Patients with pancreatic ductal adenocarcinoma with peritoneal dissemination provides a Survival Benefit. Cancers (Basel). 2022;14(5).","DOI":"10.3390\/cancers14051354"},{"key":"2526_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren J, Schwab M, Reymond MA. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21:553\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"2526_CR18","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ejso.2022.05.030","volume":"48","author":"S Frassini","year":"2022","unstructured":"Frassini S, Calabretto F, Granieri S, Fugazzola P, Vigan\u00f2 J, Fazzini N, Ansaloni L, Cobianchi L. Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(9):1911\u201321.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"2526_CR19","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1245\/s10434-022-12698-4","volume":"30","author":"G Ramos Arias","year":"2023","unstructured":"Ramos Arias G, Sindayigaya R, Ouaissi M, Buggisch JR, Schmeding M, Giger-Pabst U, Zieren J. Safety and feasibility of High-Pressure\/High-Dose pressurized Intraperitoneal Aerosol Chemotherapy (HP\/HD-PIPAC) for primary and metastatic peritoneal surface malignancies. Ann Surg Oncol. 2023;30(4):2497\u2013505.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2526_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00280-021-04318-x","volume":"88","author":"M \u00d6man","year":"2021","unstructured":"\u00d6man M, Wettergren Y, Odin E, Westermark S, Naredi P, Hemmingsson O, Taflin H. Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2021;88(4):619\u201331.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"2526_CR21","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/bjs.11792","volume":"107","author":"S Yamada","year":"2020","unstructured":"Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S. Phase I\/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. J Br Surg. 2020;107(13):1811\u20137.","journal-title":"J Br Surg"},{"key":"2526_CR22","doi-asserted-by":"crossref","unstructured":"Meguro Y, Yamaguchi H, Sasanuma H, Shimodaira K, Aoki Y, Chinen T, Morishima K, Miyato H, Miki A, Endo K et al. Combined intraperitoneal paclitaxel and systemic chemotherapy for patients with massive malignant ascites secondary to pancreatic Cancer: a report of two patients. Intern Med. 2023.","DOI":"10.2169\/internalmedicine.2191-23"},{"key":"2526_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s10637-016-0369-0","volume":"34","author":"N Takahara","year":"2016","unstructured":"Takahara N, Isayama H, Nakai Y, Ishigami H, Satoi S, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Yamaguchi H. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Investig New Drugs. 2016;34:636\u201342.","journal-title":"Investig New Drugs"},{"issue":"Suppl 1","key":"2526_CR24","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.21037\/jgo-20-243","volume":"12","author":"S Yamada","year":"2021","unstructured":"Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. J Gastrointest Oncol. 2021;12(Suppl 1):S110.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"2526_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13063-022-06049-7","volume":"23","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Fujii T, Hirano S, Motoi F, Honda G, Uemura K, Kitayama J, Unno M, Kodera Y, Yamaue H, et al. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). Trials. 2022;23(1):119.","journal-title":"Trials"},{"issue":"5","key":"2526_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/jhbp.447","volume":"24","author":"S Satoi","year":"2017","unstructured":"Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Kosaka H, Inoue K, Hashimoto Y, Matsui Y, Kon M. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution. J Hepato\u2010Biliary\u2010Pancreatic Sci. 2017;24(5):289\u201396.","journal-title":"J Hepato\u2010Biliary\u2010Pancreatic Sci"},{"key":"2526_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","volume":"77","author":"H Ueno","year":"2016","unstructured":"Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, Nakajima TE, Furuse J. Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016;77:595\u2013603.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2526_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/026567399285765","volume":"15","author":"M Urano","year":"1999","unstructured":"Urano M. Invited review: for the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperth. 1999;15(2):79\u2013107.","journal-title":"Int J Hyperth"},{"key":"2526_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1245\/s10434-017-6279-3","volume":"25","author":"M Goldenshluger","year":"2018","unstructured":"Goldenshluger M, Zippel D, Ben-Yaacov A, Dux J, Yalon T, Zendel A, Rayman S, Mor E, Berkenstadt H, Fogel-Grinvald H. Core body temperature but not intraabdominal pressure predicts postoperative complications following closed-system hyperthermic intraperitoneal chemotherapy (HIPEC) administration. Ann Surg Oncol. 2018;25:660\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"2526_CR30","first-page":"e31189","volume":"14","author":"J Nogueiro","year":"2022","unstructured":"Nogueiro J, Gomes F, Pacheco J, Santos-Sousa H, Meireles S, Bessa Melo R, Aral M, Barbosa E. Late recurrence of pancreatic solid Pseudopapillary Neoplasm with peritoneal carcinomatosis treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a Case Report. Cureus. 2022;14(11):e31189.","journal-title":"Cureus"},{"key":"2526_CR31","doi-asserted-by":"publisher","first-page":"108313","DOI":"10.1016\/j.ijscr.2023.108313","volume":"107","author":"PH Sugarbaker","year":"2023","unstructured":"Sugarbaker PH, Steves MA. Ten-year survival of pancreas cancer with liver metastases treated by intraoperative and long-term intraperitoneal gemcitabine. A case report. Int J Surg Case Rep. 2023;107:108313.","journal-title":"Int J Surg Case Rep"},{"key":"2526_CR32","doi-asserted-by":"crossref","unstructured":"Padilla-Valverde D, Bodoque-Villar R, Garc\u00eda-Santos E, Sanchez S, Manzanares-Campillo C, Rodriguez M, Gonz\u00e1lez L, Ambr\u00f3s A, Cano JM, Padilla-Marcote M et al. Safety and Effectiveness of Perioperative Hyperthermic Intraperitoneal Chemotherapy with Gemcitabine in patients with resected pancreatic ductal adenocarcinoma: clinical trial EudraCT 2016-004298-41. Cancers (Basel). 2024;16(9).","DOI":"10.3390\/cancers16091718"},{"issue":"7","key":"2526_CR33","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1158\/1078-0432.CCR-20-4342","volume":"27","author":"LA de Jong","year":"2021","unstructured":"de Jong LA, van Erp NP, Bijelic L. Pressurized intraperitoneal aerosol chemotherapy: the road from promise to proof. Clin Cancer Res. 2021;27(7):1830\u20132.","journal-title":"Clin Cancer Res"},{"key":"2526_CR34","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1245\/s10434-020-08379-9","volume":"27","author":"M Leimk\u00fchler","year":"2020","unstructured":"Leimk\u00fchler M, Hentzen JE, Hemmer PH, Been LB, van Ginkel RJ, Kruijff S, van Leeuwen BL, de Bock GH. Systematic review of factors affecting quality of life after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2020;27:3973\u201383.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2526_CR35","first-page":"482","volume":"23","author":"A-A Tentes","year":"2018","unstructured":"Tentes A-A, Pallas N, Karamveri C, Kyziridis D, Hristakis C. Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer. J buon. 2018;23(2):482\u20137.","journal-title":"J buon"},{"key":"2526_CR36","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Chang D, Koslowe P. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. In: Peritoneal Carcinomatosis: Drugs and Diseases edn. Edited by Sugarbaker PH. Boston, MA: Springer US; 1996: 89\u2013104.","DOI":"10.1007\/978-1-4613-1245-1_9"},{"issue":"4","key":"2526_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2021.12507","volume":"21","author":"A Larentzakis","year":"2021","unstructured":"Larentzakis A, Anagnostou E, Georgiou K, Vrakopoulou G-Z, Zografos CG, Zografos GC, Toutouzas KG. Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: a survival, mortality and morbidity systematic review. Oncol Lett. 2021;21(4):1\u20131.","journal-title":"Oncol Lett"},{"issue":"7","key":"2526_CR38","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.4240\/wjgs.v15.i7.1512","volume":"15","author":"JM Halle-Smith","year":"2023","unstructured":"Halle-Smith JM, Powell-Brett S, Roberts K, Chatzizacharias NA. Resection of isolated liver oligometastatic disease in pancreatic ductal adenocarcinoma: is there a survival benefit? A systematic review. World J Gastrointest Surg. 2023;15(7):1512\u201321.","journal-title":"World J Gastrointest Surg"},{"key":"2526_CR39","doi-asserted-by":"publisher","first-page":"109588","DOI":"10.1016\/j.ijscr.2024.109588","volume":"118","author":"AA Tentes","year":"2024","unstructured":"Tentes AA, Kyziridis D, Kalakonas A, Iliadis A, Fotiadou A. Pancreatic cancer with synchronous peritoneal and hepatic metastases: a case report. Int J Surg Case Rep. 2024;118:109588.","journal-title":"Int J Surg Case Rep"},{"issue":"1","key":"2526_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12328-023-01890-y","volume":"17","author":"Y Yoshizaki","year":"2024","unstructured":"Yoshizaki Y, Gohda Y, Inagaki F, Kataoka A, Takemura N, Miyazaki H, Igari T, Kiyomatsu T, Yano H, Kokudo N. A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Clin J Gastroenterol. 2024;17(1):188\u201397.","journal-title":"Clin J Gastroenterol"},{"issue":"33","key":"2526_CR41","first-page":"19","volume":"1","author":"AZ Azzam","year":"2020","unstructured":"Azzam AZ, Amin TM. Combined intraoperative Radiotherapy (IORT) and hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreduction surgery (CRS) as a Novel Approach in the management of Resectable Pancreatic Cancer. Gulf J Oncol. 2020;1(33):19\u201326.","journal-title":"Gulf J Oncol"},{"issue":"3","key":"2526_CR42","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amjsurg.2019.09.017","volume":"219","author":"EW Beal","year":"2020","unstructured":"Beal EW, Ahmed A, Grotz T, Leiting J, Fournier KF, Lee AJ, Dineen S, Dessureault S, Baumgartner JM, Veerapong J. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020;219(3):478\u201383.","journal-title":"Am J Surg"},{"issue":"2","key":"2526_CR43","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/SLA.0000000000001225","volume":"263","author":"L Schwarz","year":"2016","unstructured":"Schwarz L, Votanopoulos K, Morris D, Yonemura Y, Deraco M, Piso P, Moran B, Levine EA, Tuech J-J. Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Ann Surg. 2016;263(2):369\u201375.","journal-title":"Ann Surg"},{"issue":"13","key":"2526_CR44","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1245\/s10434-021-10263-z","volume":"28","author":"C Yurttas","year":"2021","unstructured":"Yurttas C, Horvath P, Fischer I, Meisner C, Nadalin S, Koenigsrainer I, Koenigsrainer A, Beckert S, L\u00f6ffler MW. A prospective, phase I\/II, open-label pilot trial to assess the safety of hyperthermic intraperitoneal chemotherapy after oncological resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2021;28(13):9086\u201395.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"2526_CR45","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.21037\/jgo-2020-02","volume":"12","author":"PH Sugarbaker","year":"2021","unstructured":"Sugarbaker PH, Stuart OA. Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions. J Gastrointest Oncol. 2021;12(Suppl 1):S99.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"2526_CR46","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/jso.26969","volume":"126","author":"RC Macfie","year":"2022","unstructured":"Macfie RC, Cha DE, Gleeson E, Yu A, Cohen N, Sarpel U, Golas B, Hiotis S, Labow D. Hyperthermic intraperitoneal chemotherapy does not increase risk of major complication or failure to rescue in cytoreductive surgery. J Surg Oncol. 2022;126(4):781\u20136.","journal-title":"J Surg Oncol"},{"key":"2526_CR47","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1245\/s10434-014-4186-4","volume":"22","author":"S Downs-Canner","year":"2015","unstructured":"Downs-Canner S, Ding Y, Magge DR, Jones H, Ramalingam L, Zureikat A, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol. 2015;22:1651\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2526_CR48","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/02656736.2016.1227094","volume":"32","author":"AA Tentes","year":"2016","unstructured":"Tentes AA, Stamou K, Pallas N, Karamveri C, Kyziridis D, Hristakis C. The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer. Int J Hyperth. 2016;32(8):895\u20139.","journal-title":"Int J Hyperth"},{"key":"2526_CR49","doi-asserted-by":"crossref","unstructured":"Zimmermann V, Frauenfeld L, L\u00f6ffler MW, Mihaljevic AL, Yurttas C. Long-term recurrence-free survival following pancreatic surgery with HIPEC treatment for locally advanced pancreatic adenocarcinoma. BMJ Case Rep. 2024;17(2).","DOI":"10.1136\/bcr-2023-258626"},{"issue":"7","key":"2526_CR50","first-page":"e41430","volume":"15","author":"A Elhariri","year":"2023","unstructured":"Elhariri A, Starr JS, Bagaria S, Tran N, Babiker H. A Unicorn Disease: the large Duct variant of Invasive Ductal Adenocarcinoma of the pancreas. Cureus. 2023;15(7):e41430.","journal-title":"Cureus"},{"issue":"1","key":"2526_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/pp-2022-0102","volume":"7","author":"O Sgarbura","year":"2022","unstructured":"Sgarbura O, Eveno C, Alyami M, Bakrin N, Guiral DC, Ceelen W, Delgadillo X, Dellinger T, Di Giorgio A, Kefleyesus A, et al. Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum. 2022;7(1):1\u20137.","journal-title":"Pleura Peritoneum"},{"issue":"7","key":"2526_CR52","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368\u201377.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2526_CR53","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ejso.2017.03.019","volume":"43","author":"M H\u00fcbner","year":"2017","unstructured":"H\u00fcbner M, Grass F, Teixeira-Farinha H, Pache B, Mathevet P, Demartines N. Pressurized intraperitoneal aerosol chemotherapy\u2013practical aspects. Eur J Surg Oncol (EJSO). 2017;43(6):1102\u20139.","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"2526_CR54","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00464-016-5174-5","volume":"31","author":"D G\u00f6hler","year":"2017","unstructured":"G\u00f6hler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J, Stintz M, Giger-Pabst U. Technical description of the microinjection pump (MIP\u00ae) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Endosc. 2017;31:1778\u201384.","journal-title":"Surg Endosc"},{"issue":"1","key":"2526_CR55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jviscsurg.2022.10.001","volume":"160","author":"M Pocard","year":"2023","unstructured":"Pocard M, So JBY, Huchon C, Robella M, Chavatte-Palmer P, Eveno C, Glehen O, Peng Yong W. PIPAC nebulizer: how to test the new devices in the market, expert recommendations. J Visc Surg. 2023;160(1):52\u20134.","journal-title":"J Visc Surg"},{"issue":"5","key":"2526_CR56","doi-asserted-by":"publisher","first-page":"e0300241","DOI":"10.1371\/journal.pone.0300241","volume":"19","author":"D G\u00f6hler","year":"2024","unstructured":"G\u00f6hler D, Oelschl\u00e4gel K, Ouaissi M, Giger-Pabst U. Performance of different nebulizers in clinical use for pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). PLoS ONE. 2024;19(5):e0300241.","journal-title":"PLoS ONE"},{"issue":"4","key":"2526_CR57","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ejso.2021.10.028","volume":"48","author":"M H\u00fcbner","year":"2022","unstructured":"H\u00fcbner M, Alyami M, Villeneuve L, Cort\u00e9s-Guiral D, Nowacki M, So J, Sgarbura O. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: technical aspects and treatment protocols. Eur J Surg Oncol. 2022;48(4):789\u201394.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"2526_CR58","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-20-2152","volume":"27","author":"G Kim","year":"2021","unstructured":"Kim G, Tan HL, Sundar R, Lieske B, Chee CE, Ho J, Shabbir A, Babak MV, Ang WH, Goh BC. PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res. 2021;27(7):1875\u201381.","journal-title":"Clin Cancer Res"},{"key":"2526_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2020.09.010","volume":"140","author":"F Dumont","year":"2020","unstructured":"Dumont F, Passot C, Raoul J-L, Kepenekian V, Leli\u00e8vre B, Boisdron-Celle M, Hiret S, Senellart H, Pein F, Blanc-Lapierre A. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur J Cancer. 2020;140:37\u201344.","journal-title":"Eur J Cancer"},{"key":"2526_CR60","doi-asserted-by":"crossref","first-page":"175883592094088","DOI":"10.1177\/1758835920940887","volume":"12","author":"A Di Giorgio","year":"2020","unstructured":"Di Giorgio A, Sgarbura O, Rotolo S, Schena CA, Bagal\u00e0 C, Inzani F, Russo A, Chiantera V, Pacelli F. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma. Therapeutic Adv Med Oncol. 2020;12:1758835920940887.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"2526_CR61","doi-asserted-by":"publisher","first-page":"104151","DOI":"10.1016\/j.ebiom.2022.104151","volume":"82","author":"W Ceelen","year":"2022","unstructured":"Ceelen W, Sandra L, de Sande LV, Graversen M, Mortensen MB, Vermeulen A, Gasthuys E, Reynders D, Cosyns S, Hoorens A, et al. Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases. EBioMedicine. 2022;82:104151.","journal-title":"EBioMedicine"},{"key":"2526_CR62","doi-asserted-by":"crossref","unstructured":"Roensholdt S, Detlefsen S, Mortensen MB, Graversen M. Response evaluation in patients with Peritoneal Metastasis Treated with pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). J Clin Med. 2023;12(4).","DOI":"10.3390\/jcm12041289"},{"issue":"1","key":"2526_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/jclinpath-2020-206607","volume":"74","author":"M Nielsen","year":"2021","unstructured":"Nielsen M, Graversen M, Elleb\u00e6k SB, Kristensen TK, Fristrup C, Pfeiffer P, Mortensen MB, Detlefsen S. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. J Clin Pathol. 2021;74(1):19\u201324.","journal-title":"J Clin Pathol"},{"key":"2526_CR64","doi-asserted-by":"crossref","unstructured":"Di Giorgio A, Macr\u00ec A, Ferracci F, Robella M, Visaloco M, De Manzoni G, Sammartino P, Sommariva A, Biacchi D, Roviello F et al. 10 years of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): a systematic review and Meta-analysis. Cancers (Basel). 2023;15(4).","DOI":"10.3390\/cancers15041125"},{"issue":"4","key":"2526_CR65","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1515\/pp-2023-0038","volume":"8","author":"CG Kryh-Jensen","year":"2023","unstructured":"Kryh-Jensen CG, Fristrup CW, Ainsworth AP, Detlefsen S, Mortensen MB, Pfeiffer P, Tarpgaard LS, Graversen M. What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum. 2023;8(4):147\u201355.","journal-title":"Pleura Peritoneum"},{"issue":"10","key":"2526_CR66","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ejso.2022.05.001","volume":"48","author":"M Robella","year":"2022","unstructured":"Robella M, Hubner M, Sgarbura O, Reymond M, Khomiakov V, di Giorgio A, Bhatt A, Bakrin N, Willaert W, Alyami M, et al. Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study. Eur J Surg Oncol. 2022;48(10):2212\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"2526_CR67","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10585-017-9849-7","volume":"34","author":"M Graversen","year":"2017","unstructured":"Graversen M, Detlefsen S, Bjerregaard JK, Pfeiffer P, Mortensen MB. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Clin Exp Metastasis. 2017;34:309\u201314.","journal-title":"Clin Exp Metastasis"},{"issue":"10","key":"2526_CR68","doi-asserted-by":"publisher","first-page":"e0186709","DOI":"10.1371\/journal.pone.0186709","volume":"12","author":"T Khosrawipour","year":"2017","unstructured":"Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized intra peritoneal aerosol chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS ONE. 2017;12(10):e0186709.","journal-title":"PLoS ONE"},{"issue":"6","key":"2526_CR69","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/bjs.10521","volume":"104","author":"F Grass","year":"2017","unstructured":"Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, H\u00fcbner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. J Br Surg. 2017;104(6):669\u201378.","journal-title":"J Br Surg"},{"issue":"9","key":"2526_CR70","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.7314\/APJCP.2012.13.9.4379","volume":"13","author":"J-Y Huang","year":"2012","unstructured":"Huang J-Y, Xu Y-Y, Sun Z, Zhu Z, Song Y-X, Guo P-T, You Y, Xu H-M. Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4379\u201385.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"9","key":"2526_CR71","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127(9):2209\u201321.","journal-title":"Int J Cancer"},{"issue":"11","key":"2526_CR72","first-page":"4272","volume":"7","author":"Y-Q Ai","year":"2014","unstructured":"Ai Y-Q, Cai K, Hu J-H, Jiang L-W, Gao Y-R, Zhao H, Jia S-C. The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int J Clin Exp Med. 2014;7(11):4272.","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"2526_CR73","first-page":"101","volume":"34","author":"MA Str\u00f6hlein","year":"2011","unstructured":"Str\u00f6hlein MA, Lordick F, R\u00fcttinger D, Gr\u00fctzner K-U, Schemanski OC, J\u00e4ger M, Lindhofer H, Hennig M, Jauch K-W, Peschel C. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I\/II trial. Oncol Res Treat. 2011;34(3):101\u20138.","journal-title":"Oncol Res Treat"},{"key":"2526_CR74","doi-asserted-by":"publisher","first-page":"101662","DOI":"10.1016\/j.tranon.2023.101662","volume":"32","author":"GA McCarthy","year":"2023","unstructured":"McCarthy GA, Jain A, Di Niro R, Schultz CW, Jiang W, Yeo CJ, Bowers J, Finan J, Rhodes K, Casta L, et al. A novel 3DNA\u00ae nanocarrier effectively delivers payloads to pancreatic tumors. Transl Oncol. 2023;32:101662.","journal-title":"Transl Oncol"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-024-02526-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12893-024-02526-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-024-02526-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:04:12Z","timestamp":1728007452000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-024-02526-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2526"],"URL":"https:\/\/doi.org\/10.1186\/s12893-024-02526-9","relation":{},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}